Browsing Tag
obesity trial
1 post
Ascletis doses first obesity patients in U.S. Phase IIa trial of once-monthly GLP-1R depot ASC30
Ascletis (HKEX: 1672) begins dosing in U.S. Phase IIa obesity trial of ASC30, its once-monthly small molecule GLP-1R agonist, with topline data expected Q1 2026.